Determination of A-Protein Levels in Adult and Pediatric Brain Tumor Patients
N/A
77 Years
Both
Malignant or Benign Lesions of the Central Nervous System
Trial Information
Determination of A-Protein Levels in Adult and Pediatric Brain Tumor Patients
- Patients will be identified at the time of presentation to their neurologist,
neurosurgeon or oncologist.
- Blood or cerebrospinal fluid will be collected for this study only when they are being
collected for other reasons before and after each surgery. Samples will also be
collected after any event such as significant change in symptoms or radiographic
progression.
- Once the patients condition has been stabilized, samples will be take at regular
intervals of >= 1 month. The duration of this study is 24 months.
Inclusion Criteria:
- All patients with possible malignant or benign lesions of the central nervous system
will be included.
- There are no restrictions with respect to treatment protocols or prior therapy.
- Patients will be identified after presentation to the neurosurgical, neurological or
oncologic services at participating centers. Any patient with evidence of a central
nervous system tumor will be eligible. Individuals without evidence of CNS tumors are
also eligible, in order to provide blinded controls.
- A signed informed consent will be requested and required for participation.
- There is no age, sex, or ethnic origin restrictions in this protocol. Patients who
choose not to participate in the study will continue to have their regular care as
defined by their treating team. Patients who speak foreign languages are eligible as
long a translator can be found to ensure proper consent has been obtained.
Exclusion Criteria: There are no exclusion criteria for this study.
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
The purpose of this study is to evaluate the usefulness of a molecule called "A-Protein" in the diagnosis and evaluation of patients with central nervous system disorders.
Outcome Time Frame:
24 months
Safety Issue:
No
Principal Investigator
Mark W Kieran, MD,PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Dana-Farber Cancer Institute
Authority:
United States: Institutional Review Board
Study ID:
98-137
NCT ID:
NCT00165542
Start Date:
June 1998
Completion Date:
February 2010
Related Keywords:
- Malignant or Benign Lesions of the Central Nervous System
- A-protein level
- brain tumor
- Brain Neoplasms
Name | Location |
|---|---|
| Dana Farber Cancer Institite | Boston, Massachusetts 02115 |
